mt logoMyToken
ETH Gas
日本語

Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

収集collect
シェアshare

Moderna Hits Fresh 52-Week High as Bernstein Calls Intismeran Clearest mRNA Platform Validation, Keeps $45 Target

Moderna Inc. (NASDAQ: MRNA) shares set a fresh 52-week high Friday before giving back the intraday advance, while Bernstein SocGen Group reiterated its Market Perform rating and $45 price target and called intismeran the clearest validation yet of Moderna’s broader mRNA therapeutics platform.

Visit Website

免責事項:この記事の著作権は元の作者に帰属し、MyTokenを表すものではありません(www.mytokencap.com)ご意見・ご感想・内容、著作権等ご不明な点がございましたらお問い合わせください。
MyTokenについて:https://www.mytokencap.com/aboutusこの記事へのリンク:https://www.mytokencap.com/news/597901.html
community_x_prefix
X(https://x.com/MyTokencap)
community_tg_prefixcommunity_tg_name
(https://t.me/mytokenGroup)
関連読書